CTOs on the Move

Dyno Therapeutics

www.dynotx.com

 
Dynotx.com provides cutting-edge sales and marketing tools for small and medium-sized businesses. Their services include web design, social media management, advertising, and SEO optimization. They aim to help businesses grow and succeed online by prov...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dynotx.com
  • 343, Arsenal Street
    Watertown, MA USA 02472
  • Phone: 857.242.0593

Executives

Name Title Contact Details

Similar Companies

M2Gen

M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company`s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. M2GEN`s Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to the fight against cancer for patients today and tomorrow. M2GEN currently has more than 300,000 total consented patients across a network of 18 cancer centers in 10 states.

Tactical Therapeutics

Tactical Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proteonomix

The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.